trending Market Intelligence /marketintelligence/en/news-insights/trending/XZiUuBaBus8rBspWQsmb4w2 content esgSubNav
In This List

KKR completes $1.4B acquisition of PharMerica


According to Market Intelligence, December 2022


Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes


Spotlight on sustainability: How banks can overcome the challenges of achieving net-zero emissions by 2050


Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

KKR completes $1.4B acquisition of PharMerica

KKR & Co. LP completed the $1.4 billion acquisition of PharMerica Corp. via a newly formed company that counts drugstore chain Walgreens Boots Alliance Inc. as a minority investor.

PharMerica shareholders will receive $29.25 per share in cash from KKR.

The acquisition takes PharMerica private and its shares will cease trading on the NYSE before the markets opens Dec. 8.

In November, stockholders of PharMerica, a provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, approved the takeover of the company.

UBS Investment Bank and Bank of America Merrill Lynch are serving as financial advisers to PharMerica and Davis Polk & Wardwell LLP is serving as the company's legal adviser.

Simpson Thacher & Bartlett LLP and Weil Gotshal & Manges LLP are serving as legal advisers to KKR and Walgreens Boots Alliance, respectively.